Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Regeneron argues that it can’t be certain the deals don’t unfairly advantage other Sanofi products at Dupixent’s expense. Dupixent is a critical drug for both Regeneron and Sanofi ...

Sanofi’s sale of its $17bn consumer health ... The medicine is so popular that most paracetamol products are referred to as Doliprane, regardless of the manufacturer. In addition, Opella ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...